Spiolto ® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news